Pregabalin Dispensing Patterns in Amman-Jordan: an Observational Study from Community Pharmacies by Al-Husseini, A et al.
Pregabalin Dispensing Patterns in Amman-Jordan: an Observational Study 
from Community Pharmacies  
 
Amneh Al-Husseini1 MSc,  Rana Abu-Farha2* PhD,  Mayyada Wazaify1 PhD,  Marie Claire Van 
Hout3 PhD 
 
1. Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University 
of Jordan (UJ), Amman, Jordan. 
2. Department of Clinical Pharmacy and Therpeutics, Faculty of Pharmacy, Applied Science 
Private University, Amman, Jordan. 
3. Public Health Institute, Liverpool John Moore’s University, United Kingdom  
 
 
*Address for correspondence and reprints:  
Rana Abu Farha, BPharm, MSc, PhD 
Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy 
Applied Science Private University. Amman-Jordan.  
. r_abufarha@asu.edu.jo, abufarharana@yahoo.comEmail:  
Tel: 0096265609957 ext 1496; Fax: 009625232899, PO. 11931 
 
 
 
 
  
Pregabalin Dispensing Patterns in Amman-Jordan: an Observational Study 
from Community Pharmacies  
 
Abstract 
Objectives: Pregabalin is currently approved for the treatment of epilepsy, generalized anxiety 
disorder, neuropathic pain and fibromyalgia. Rising attention to the abuse liability of pregabalin 
causing addictive behaviors is partially based on case reports and published literature of pregabalin 
used in dosages that override the approved therapeutic range. This study was conducted to provide 
background data regarding the abuse/misuse of pregabalin from community pharmacy in Jordan.  
Methods: A prospective cross-sectional observational study design was used, which was 
conducted at different community pharmacies in Amman-Jordan. During the study period 
(November 2016-January 2017), a total 77 requests for pregabalin were observed from 14 
pharmacies. A structured interview was conducted with all customers to gather information 
regarding their demographic and their request of pregabalin. 
Results: A total of 77 pregabalin requests form 77 customers in a community pharmacy setting 
were observed in this study. Spinal disc herniation was the most common complaint for which the 
customer asked for the medication (n= 27, 35.1%). Self-medication was the most frequent method 
of requesting pregabalin (n= 44 , 57.1%), while a total of 33 customers (42.9%) asked for the 
product using a prescription. During the observation period the number of customers suspected of 
abusing pregabalin for non-medical reason was 35 (45.5%). A total of 33 out of the 35  suspected  
customers (94.3%) asked for the product without a prescription, and 19/35 weren‘t sold due to 
suspicion of abuse (54.3%).  
Conclusion: The study underscores the need for regulatory efforts to manage pregabalin abuse, 
through the addition of  pregabalin containing products to the controlled drug list which can’t be 
purchased without a prescription. Also, pharmacists and customers must be educated at a 
community pharmacy level regarding potential  hazards of pregabalin abuse. 
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1. Introduction 
Substance use disorder is a group of behavioral, cognitive and physiological symptoms resulting 
from applying the substance continuously despite significant negative effects (Kerridge et al., 
2017). It may result as a consequence of drug abuse and misuse. “Misuse” is a broad term which 
comprises many different forms of problematic consumption where the use of the substance does 
not follow medical instructions (Bronstein et al., 2011; Casati et al., 2012) while the term “abuse” 
refer to situation where the substance be used for nontherapeutic purposes to obtain psychotropic 
effects (Cicero et al., 2007). By definition, any medication can be misused, but only few have the 
abuse potential, such as those with mind-altering or body-shaping properties (Cooper 2013).  
The risks of addiction to prescription drugs rise when they are used in means other than prescribed 
(e.g. at higher doses, by other routes of administration, or mixed with alcohol or other drugs) 
(NIDA 2014). The most commonly reported prescription medications to be abused worldwide are 
stimulants such as methylphenidate, central nervous system depressants such as sedatives 
(benzodiazepines) or some anticonvulsants like clonazepam (NIDA 2014) or pregabalin (Loftus 
and Wright 2014).  
Pregabalin is an analogue of the gamma-aminobutyric acid mammalian neurotransmitter. They act 
as inhibitory modulators of neuronal excitability that reduce ectopic neuronal activation of 
hyperexcited neurons while normal activation remains unaffected (Papazisis and Tzachanis 2014). 
Pregabalin is approved for the treatment of partial epilepsy; generalized anxiety disorder; 
peripheral and central neuropathic pain and fibromyalgia with an accepted dosage range of 150 to 
600 mg/day (Papazisis and Tzachanis 2014). 
In Jordan, like other countries in the region, with the exception of controlled drugs, it is possible 
to buy any medicine without a prescription. This availability linked with relatively low price 
products and availability of pharmacies is speculated to lead to abuse of a wide vriety of  OTC and 
prescription drugs (Albsoul-Younes et al., 2010). In  2014 a study was conducted by Wazaify et 
al. to document any change that may have happened in the type and frequency of suspected 
abuse/misuse of medications that can be bought without prescription from community pharmacies 
in Jordan (Wazaify et al., 2017a). A recent concerning trend was the abuse of the anticonvulsant 
drug (pregabalin), which obtained from pharmacies without a prescription and was not been 
mentioned previously in Jordan (Wazaify et al., 2017a)  
In  2014 a formal statement about the restriction of pregabalin products dispensing in Jordan 
appeared (JFDA 2014). This was due to the occurrence of spontaneous reports which was observed 
by the Jordan Food and Drugs Administration (JFDA) pharmacovigilance center regarding 
pregabalin abuse containing products. Pregabalin containing products were placed on the  list of 
restricted drugs use that require a medical prescription to dispense it. This list includes drugs with 
abuse liability, but not competent to be under scheduled controlled drugs (JFDA 2014). But 
unfortuanatly, it is still possible to get such medications easily without fearing of legal 
accountability.   
In 2017 another announcement was released in Jordan to emphasize the obligation on not to supply 
samples of drugs containing this substance or grant quantities of incentives on the quantities sold 
of this medicine (JFDA 2017). Despite this announcement the pregabalin products still can be sold 
without a prescription and without fear of any legal accountability. So efforts are needed to support 
the addition of this drug to the controlled drug list (which can’t be purchased without prescription 
in Jordan). In order to support this requirement, we aimed in this observational study to provide 
background data regarding the abuse/misuse of pregabalin products in a community pharmacy 
setting in Jordan. Up to the researchers’ knowledge, this is the first study of its kind in Jordan to 
address this issue. 
2. Methods 
2.1 Study design, setting and subjects 
The study was designed as a prospective cross-sectional observational study that was conducted 
at different community pharmacies in Amman, the capital of Jordan. Two researchers interviewed 
all customers of a number of community pharmacies asking for pregabalin products during the 
observational period (November 2016-January 2017). Customers verbally consenting to be 
interviewed. 
A convenience sampling technique was used to select the involved pharmacis. This was based on 
the feasibility, geographical proximity to the researchers housing, and upon consenting to 
participate by the pharmacy manager of each community pharmacy. Researchers took every effort 
to cover most socioeconomic regions in Amman (Dahiyat ALrasheed, Al-Jandaweel, Sweifieh, 
Sweileh, Khalda, Jbeiha, Sahab, Wadi-Alseir, Khrbet Alsouq, and Arjan).  
2.2 Data collection instrument 
Researchers used a pre-tested and pre-piloted data collection form which was adopted from 
Wazaify et al. 2017 study (Wazaify et al., 2017b). The method used in this study was a structured 
interview with all customers presented at the time of the survey. The data collection form was 
designed to gather customers information in an anonymous way without mentioning any 
information belonging to customers or pharmacists.  
Information obtained in the interview include: 1) customers’ demographic data including (age, 
gender and academic qualification, site of recruitment and shift of recruitment), 2) pharmacies and 
pharmacists information (pharmacy location, chain or independent pharmacy,  pharmacists age, 
gender, and experience), 3) the name of pregabalin product, quantity, indication and duration of 
use, 4) the way of asking for the medication (prescription, customers’ request (self-medication), 
or pharmacist dispenses), and 5) pharmacist response with the abuser customers and the signs that 
led the pharmacists and the researchers to suspect them, for example (the pattern and repeated 
requests, customers's appearance (if he confused or related to his face), pharmacists’ familiarity 
with customers and the quantity requested). 
2.3 Data collection procedure 
A predetermined schedule was designed in order to observe each community pharmacy for one 
week. Data collection took place over November 2016-January 2017 through 14 pharmacies at 
different regions of Amman. Data were filled by the researchers after informing the pharmacists 
within pharmacies that the aim of this research was to measure the pregabalin drug misuse/abuse 
among customers in community pharmacies. To minimize the observers’ effect (i.e. Hawthorne 
effect), the researchers noticed the interaction between customer and pharmacist standing beside 
the pharmacist on the dispensing counter, wearing lab coats. A collaboration was made between 
the researchers and the main pharmacists to detect the abuser customers. The data collection form 
was filled immediately after observations and any additional information thought to be important 
to the research was written at the end of the data collection form. Each researcher was the only 
observer in each community pharmacy. 
2.4 Ethical Consideration  
This study was approved by Jordanian Ministry of health (Reference number: MOH REC170012). In 
addition, verbal consents were obtained from all pharmacists to use their demographic data. Written 
and signed consent forms were obtained from the pharmacy managers for their acceptance for the study 
to be conducted in their pharmacies.  
2.5 Statistical analysis  
All data were coded and entered into the Statistical Package for Social Sciences (SPSS) database 
(version 22) for statistical analysis (IBM Corporation, Armonk, NY, USA). Descriptive data were 
summarized as counts and percentages for categorical variables and mean and SD for continuous 
variables.  
 
Univariate statistical analysis including chi square and  Fisher exact tests were used to detect 
factors affecting pregabalin products selling among abuser patients. A p-value less than 0.05 was 
considered significant throughout the analysis. 
 
3. Results 
3.1 Demographic characteristics of recruited pharmacists/pharmacies 
Out of nineteen pharmacies who were approached, fourteen agreed to take part in the study, 
resulting in a response rate of 73.6%. The reason for rejection was mainly the lack of interest of 
the responsible pharmacist in this kind of research. Around 86% (n= 12) of the involved 
pharmacies were independent pharmacies, while the remaining 14% (n= 2) were chain pharmacies. 
Ten pharmacies (71.4%) were located in west Amman (areas with higher socioeconomic status) 
and seven pharmacies (50.0%) on a main road. Most of the pharmacists working in these 
pharmacies were females (n=8, 57.1%) and half  (n=7, 50%) aged between 20-30 years. Social 
demographic details of involved pharmacists/pharmacies participating in the study are summarized 
in Table 1.  
3.2 Demographic characteristics of study participants 
For the total 14 pharmacies observed for the whole study duration, a total of 77 requests were 
reported for pregabalin. The average number of pregabalin product requests was 5.5 
product/pharmacy. All of those 77 customers were interviewed, most of whom were male (n=55, 
71.4%) and between 21-40 years (n=51, 66.2%), respectively. More than one-third of customers 
(n=32, 41.6%) held a Bachelor degree. Most of the observations (n=72, 93.5%) were recruited 
from independent pharmacies and during shift B working (ie- 4pm-12am; n=53, 68.8%). No 
observations were made during working shift C (12am-8am) due to lack of research assistants 
covering this period. Demographic characteristics of customers are presented in Table 2. 
3.3 Information regarding dispensed pregabalin products 
Various neurologic complaints were presented by observed customers during the study period. The 
top two complaints were spinal disc herniation (n=27, 35.1%) and chronic generalized pain (n=17, 
22.1%). Eight customers (10.4%) came to pharmacies asking for a specific pregabalin product and 
mentioned wanting this specific medication (pregabalin) to feel the mood and get rest. Six 
customers (7.8%) also came to ask for specific pregabalin product and mentioned preferring the 
product for their psychological stress and anxiety. Several causes of the complaints were reported 
and included neuropathic pain, back or knee pain, muscle strain, fatigue, insomnia, and for his/her 
colon. Others refused to mention the complaints and argued that the product was for his/her mother 
or friend. A summary of complaints reported by customers is presented in Table 3.  
Observed customers were divided into two groups: those requesting a specific pregabalin product 
by name (direct self-medication) (n= 44, 57.1%) and those presenting with a prescription of  
pregabalin (n= 33, 42.9%). Concerning indirect self-dispensing by pharmacists, there was no 
observable  role of the pharmacist during the study period in prescribing pregabalin product for 
customers. 
Regarding pregabalin products; the most commonly prescribed products were Lyrica® (n=26, 
33.8%), followed by Zega® (n=16, 20.8%). From pregabalin products, Zega® was the most 
frequently requested by direct self-medication method (n=13/16, 81.2%). Concerning pregabalin 
concentrations; the most frequently prescribed concentrations were 150 mg (n=37, 48.1%), 
followed by 75 mg (n=30, 39.0%). Whereas 150 mg was the most concentrations requested by 
direct self-medication method, (n=25/37, 67.6%). A description of the pregabalin 
products/concentrations requested during the study are presented in Table 4.  
The analysis revealed that most observed customers (n=54, 70.1%) asked specifically for  
pregabalin product in packs (range from one to three packs), while 23 customers (29.9%) asked 
specifically for one strip of pregabalin product. The total number of packs of pregabalin product 
requested during the study period was 63 packs. 
3.4 Misuse/abuse evaluation among study observed customers 
Over the eight-week study period, 35 observed cases (45.5%) were suspected of pregabalin abuse. 
These suspected cases involved six pregabalin products of abuse; Lyrica® in ten cases, Galica® in 
ten cases, Zega® in nine cases, Neogaba® in three cases, Regab® in two cases, and Epigab® in one 
case. In these suspected cases pregabalin concentrations of abuse were 150 mg in 18 cases.  
During the observation, information regarding customers suspected of abuse was collected. Almost 
all suspected abusers were male (32/35, 91.4%), and aged between 21-40 years (30/35, 85.7%). 
Most of them (33/35, 94.3%) presented no prescription and asked for the medication by name, 
whereas two of them (5.7%) had brought prescription to get pregabalin products.  
Regarding pharmacist responces in selling the drug for suspected customers, responses were 
diverse; where the product was sold in 16 cases (45.7%) and not sold in remainder (n= 19, 54.3%). 
Among the 19 cases where the productes were not sold, in 6 cases (17.1%) the pharmacist did not 
sell the requested product and claimed that the product was not available. In 10 cases, the 
pharmacist did not sell the requested product because of lack of prescription (28.6%), and in 3 
cases (8.6%) the pharmacist did not sell the products because the drug was not actually in stock. 
Almost all customers 34/35 (97.1%) reported previously using the same drug they had requested. 
Customers’ complaints, customers’ familiarity, suspicious reasons and all the details are presented 
in Supplementary table S1. 
 
3.5 Factors affecting pregabalin products selling among abuser patients  
The demographic details (pharmacist gender, age and year of experience, and pharmacy location, 
type and at which road) of pharmacists and pharmacies participating in the study did not appear to 
be significantly affecting the selling among abuser patients (p> 0.05).  
4. Discussion 
To the best of authors' knowledge, this is the first study of its kind in Jordan to prospectively 
observe pregabalin products abuse/misuse in community pharmacy. This study presents noval data 
around the types of products and motives for pregabalin abuse in this country, and describes current 
methods that pharmacists use to manage such requests. Studies at present are restricted to 
measuring the abuse/misuse potential of pregabalin in general at different pharamcovigilance 
databases or by evaluating the prevalence of pregabalin abuse/misuse issue (Bossard et al., 2016; 
Schjerning et al., 2016; Schwan et al., 2010; Wazaify et al., 2017a). 
One of the strengths of this study is the prospective observation on real cases in a community 
pharmacy setting. In this study customers-pharmacist interactions involving pregabalin products 
were observed at different community pharmacies in Amman. Among the observed customers in 
this study, 71.4% were males. This was similar to a German study which was conducted to measure 
the number of cases of pregabalin abuse or dependence, where 64% of cases were male (Gahr et 
al., 2013).   
It was found that the most common complaint reported by customers buying pregabalin from 
pharmacies was spinal disc herniation, followed by chronic generalized pain and neuropathic pain. 
In a German study, neuropathic pain was the most common medical indication for treatment with 
pregabalin reported by the Federal Institute for Drugs and Medical Devices database of ADR (Gahr 
et al., 2013).  
In this study, Lyrica® followed by Zega® were the most commonly dispensed pregabalin products. 
Lyrica® as a product liable for abuse appeared in the literature from Jordan for the first time in 
2014 (Wazaify et al., 2017a). It was not registered as a product liable for abuse in 2006 during the 
evaluation of misuse and abuse of prescription drugs in Jordan (Albsoul-Younes et al., 2010). 
Popularity of Lyrica® may have been driven by pharmacist sales incentives. In order to tackle this 
problem the JFDA released a new announcement in 2017, in particular for drug stores, not to grant 
incentives on the quantities sold of medicines containing pregabalin (JFDA 2017).  
The most frequently dispensed concentration of pregabalin was 150 mg, followed by 75 mg. 
Similar finding was obseverd in a previous study, which aimed to characterize customers 
dispensed pregabalin at higher than the maximum allowed dose based on data extracted from 
Swedish national registers (Bodén et al., 2014). In this cohort study, a higher pregabalin strengths, 
were the most concentrations reported (Bodén et al., 2014).  
Self-medication, whereby the customer requested  specific medication by name without a 
prescription, was the most frequently reported pattern of sale in all pregabalin products (57.1%). 
This was similar to a Jordanian study conducted to measure self-medication patterns of all drugs 
supply that took place in the pharmacies, with self-medication was reported by 42.5% of 
Jordanians (Yousef et al., 2008). It is worth mentioning that in our study there was no role of 
pharmacists in prescribing pregabalin by indirect self- medication, since it is classified in Jordan 
as a prescription only medicine that require a written prescription by a physician (JFDA 2014). 
This may be due to the observer effect where pharmacists may have behaved differently in the 
presence of the researchers. 
Also, it was noted that some customers requested pregabalin (29.9%) by a strip without the outer 
package, which is considered illegal by JFDA (JFDA 2017). This is concerning as one of the major 
stabilizing influences of packaging is to maintain storage conditions and protection from moisture. 
That moisture can affect a product’s chemical and physical stability, which lead to a change in the 
expiration date of a drug product, and to a change in any of a drug product performance (e.g., 
dissolution, hardness) or appearance, if the drug found without its outer package (Waterman and 
MacDonald 2010).  
The high percentage of self-medication of pregabalin products in our study revealed a very low 
level of public awareness regarding safe use of this drug. Serious medical consequences such as 
psychotic symptoms with rhythmic EEG-changes can occur due to pregabalin product 
abuse/misuse (Olaizola et al., 2006). The generic brand Zega® was most frequently requested 
product by direct self-medication method. The bio-equivalence of the generic drug from the 
original brand may explain the increase in demand of the generic brand of pregabalin, which are 
cheaper. 
During the observation period of 14 pharmacies, the number of customers suspected of abusing 
pregabalin was 35 (45.5%). Those cases were suspected, according to the pharmacist' prior 
knowledge of the customer. This high suspected abuse rate may have arisen since these 
medications are not scheduled as drugs of abuse by JFDA (JFDA 2014), as well as the customer 
can get such medications easily without fearing of legal accountability. Selling pregabalin to 
suspected abused was not found to be associated with any pharmacy related sociodemographic 
characteristics. 
The finding of the study should be interpreted with the two main limitations in mind. Firstly, the 
study was conducted in a single city at Amman, capital of Jordan, and hence the results might not 
be generalizable. Secondly, although every effort had been made to assure pharmacists of the 
confidentiality and anonymity of the study and that it is done solely for research purposes by an 
academic team. Still, the Hawthorn effect could not be totally negated, as some pharmacists may 
have behaved differently in the presence of the researchers, which may have affected the results.  
5. Conclusion 
All these findings call the attention for implementation of effective community pharmacy based 
interventions to raise customer, neurologist and pharmacist awareness and ultimately reduce the 
abuse rate of pregabalin products. Also, these findings should support the appeal for the addition 
of pregabalin preparations to controlled drugs list (which can’t be purchased without prescription 
in Jordan). 
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Table 1. Social demographic details of involved pharmacists/pharmacies participating in the study 
(N=14) 
 
Variable N % 
Age  
20-30 years 7 50% 
31-40 years 6 42.9% 
41-50 years 0 0 
>50 years 
 
1 
 
7.1% 
 
Gender 
Male 6 42.9% 
Female 
 
8 57.1% 
Experience 
<1 year  1 7.1% 
1-5 years 3 21.4% 
6-10 years 6 42.9% 
>10 years 4 28.6% 
 
Type of pharmacy 
Chain pharmacy 2 14.3% 
Independent pharmacy 12 85.7% 
 
Location of pharmacy  
East Amman (low socioeconomic status) 4 28.6% 
West Amman (high socioeconomic status)   10 71.4% 
 
The road type 
Main street  7 50% 
Side / sub street 
 
7 
 
50% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Demographic Characteristics of study Participants requesting pregabalin products from 
community pharmacies (N=77).  
 
Variable N % 
Age  
< 20 years 5 6.5% 
21-40 years 51 66.2% 
41-50 years 12 15.6% 
50-60 years 8 10.4% 
>60 years 
 
1 
 
1.3% 
 
Gender 
Male 55 71.4% 
Female 
 
22 
 
28.6% 
 
Academic qualification 
Undergraduate  10 13% 
Community colleges / Diploma 4 5.2% 
Bachelor's degree 32 41.6% 
High degree 1 1.3% 
Don’t know 
 
30 
 
39% 
 
Site of recruitment 
Chain Pharmacy 5  6.5% 
Independent pharmacy   
 
72 
 
93.5% 
 
Shift of recruitment 
A (8am-4pm) 24 31.2% 
B (4pm-12am) 
 
53 
 
68.8% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Complaints presented by customers during the study period (N=77) 
Customer Complaints N % 
Disc 27 35.1% 
Chronic Pain* 17 22.1% 
Neuropathic Pain 9 11.7% 
Mood and Rest 8 10.4% 
Stress and Anxiety 6 7.8% 
Other ** 4 5.2% 
Muscle strain 2 2.6% 
Fatigue and Exhaustion 2 2.6% 
Insomnia 1 1.3% 
For Colon 1 1.3% 
*Chronic Pain: e.g. back pain, knee pain or joint pain. 
**Other: e.g. refuse to mention, e.g. for a family member or friend. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Pregabalin products/concentrations used by the customers (N= 77) 
Pregabalin products used by the customers Description method of request* 
Pregabalin products N % Prescription Self-medication 
Lyrica® 26 33.8% 14 (53.8%) 12 (46.2%) 
Zega® 16 20.8% 3 (18.8%) 13 (81.2%) 
Galica® 13 16.9% 4 (30.8%) 9 (69.2%) 
Regab® 11 14.3% 7 (63.6%) 4 (36.4%) 
Neogaba® 7 9.1% 3 (42.8%) 4 (57.2%) 
Epigab® 4 5.2% 2 (50.0%) 2 (50.0%) 
Total 77 100% 33 (42.9%) 44 (57.1%) 
Pregabalin concentrations used by the customers Description method of request* 
Pregabalin concentrations N % Prescription Self-medication 
150 mg 37 48.1% 12 (32.4%) 25 (67.6%) 
75 mg 30 39.0% 17 (56.7%) 13 (43.3%)  
300 mg 9 11.7% 3 (33.3%) 6 (66.7%) 
50 mg 1 1.3% 1 (100%) 0 (0%) 
Total 77 100% 33 (42.9%) 44 (57.1%) 
*percentage were calculated per each row 
 
Table S1. Details of the observed cases suspected of pregabalin drug abuse during the study (N=35) 
# Chain / 
Independent  
Pharmacy 
Participant 
gender/age 
Pregabalin 
product/ 
conc./ 
Quantity 
Request 
method 
Used 
before? 
Compliant by 
customer 
Customer 
Familiarity 
Pharmacist 
response  / reason, 
if not sold 
Suspicious reasons 
1 Independent 
 
 
 
Male 
21-40 years 
Galica® 
/ 300 mg 
1 strip 
By 
customer 
without 
prescription 
Yes Back pain Familiar Sold the drug Unconvincing request of the 
customer with apparent 
symptoms. 
2 Independent 
 
 
 
 
Male 
21-40 years 
Zega® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Back pain for his 
mother 
Non 
Familiar 
The drug is not 
existing  
Irrational story when the 
customer narrated it and not 
matched the symptoms.  
3 Independent Male  
Less than 
20 years 
 
Epigab® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Refuse to mention for 
his mother 
Familiar The drug is not 
existing  
The way of asking with 
appearance of concern and 
tension.  
4 Independent Male  
21-40 years 
 
 
 
Lyrica® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes To induce rest and joy Non 
Familiar 
The drug is not 
existing  
The customer stated that he used 
Lyrica® for the purposes of 
abuse. Also, he expressed his 
willingness to bring a 
prescription.  
5 Independent 
 
 
 
Male  
21-40 years 
 
 
 
Galica® 
/ 300 mg 
1 strip 
By 
customer 
without 
prescription 
Yes  Muscle strain in his 
back  
Non 
familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
Lack of justification for using 
the drug in that complaint, no 
prescription and the pharmacist 
dispensed safer muscle relaxant. 
6 Independent Male  
21-40 years 
Lyrica® 
/ 150 mg 
1 pack 
 
 
By 
prescription 
written by 
general 
doctor 
Yes Chronic pain and 
exhaustion 
Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
 
The pharmacist told that 
prescription is irrational as it 
contain also Lexopam® and for 
young aged customer. 
7 Independent Male 
21-40 years 
Galica® 
/ 300 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Spinal disc Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
 
Because the customer requested 
2 pack of the drug urgently for 
traveling and he was confused 
when requesting the drug. 
# Chain / 
Independent  
Pharmacy 
Participant 
gender/age 
Pregabalin 
product/ 
conc./ 
Quantity 
Request 
method 
Used 
before? 
Compliant by 
customer 
Customer 
Familiarity 
Pharmacist 
response  / reason, 
if not sold 
Suspicious reasons 
8 Independent Male  
21-40 years 
 
Neogaba® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription  
Yes Spinal disc Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription. 
 
Because the customer has no 
prescription and young in age. 
9 Independent Male  
21-40 years 
Galica® 
/ 300 mg 
1 pack 
By 
prescription 
written by 
orthopedic 
doctor 
Yes Spinal disc Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
The pharmacist told that this 
customer has lack of clarity in 
the reason for using the drug, in 
the beginning he said he using it 
as hypnotic then he said for his 
disc.  
10 Independent Male  
21-40 years 
Lyrica® 
/ 150 mg 
2 pack 
By 
customer 
without 
prescription 
Yes Spinal disc Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
Because the pharmacist in shift 
B told that the customer himself 
stated that he used to buy the 
drug in high quantities, then he 
will sell it in expensive prices to 
drug abusers.  
 
11 Independent Male 
21-40 years 
Neogaba® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
Yes For Insomnia Familiar Sold  the drug Because the customer himself 
stated that he used it for 
relaxation and to sleep. 
12 Independent Male  
21-40 years 
Zega® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Knee pain   Non 
Familiar 
Sold  the drug  The customer told that his doctor 
stopped the treatment with this 
drug, but he can’t feel rest at 
night without it.  
13 Independent Male 
41-50 years 
Lyrica® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes Spinal disc for his 
mother 
 Familiar Sold the drug  The pharmacist told that this 
customer always come to the 
pharmacy and ask for Lyrica® 
and every time with different 
reason. 
 
14 Independent Male  
21-40 years 
Zega® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes Spinal disc for his 
mother 
Non 
Familiar 
Sold the drug Because when the customer 
requesting the drug. He calls his 
friend as the drug for his mother.  
# Chain / 
Independent  
Pharmacy 
Participant 
gender/age 
Pregabalin 
product/ 
conc./ 
Quantity 
Request 
method 
Used 
before? 
Compliant by 
customer 
Customer 
Familiarity 
Pharmacist 
response  / reason, 
if not sold 
Suspicious reasons 
15 Independent Male  
21-40 years 
Regab® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
Yes For colon Familiar Sold the drug Because of unjustified use the 
drug for colon. As the customer 
stated that he improve with it. 
16 Independent Female 
Less than 
20 years 
Lyrica® 
/ 150 mg 
1 strip 
By 
prescription 
written by 
general 
doctor 
 
Yes Refuse to mention for 
her sister 
Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
 
Because of unconvincing request 
of the customer that the drug for 
her sister and young in age. 
17 Independent Male  
21-40 years 
Galica® 
/ 300 mg 
1 strip 
By 
customer 
without 
prescription 
 
Yes Spinal disc Familiar Sold the drug The pharmacist told that this 
customer repeatedly requesting 
the drug with different diagnosis.  
18 Independent Male  
Less than 
20 years 
Zega® 
/ 75 mg 
2 pack  
By 
customer 
without 
prescription 
Yes For pain Familiar Sold the drug The pharmacist told that this 
customer always asked for this 
drug in large quantities. As on 
the first time he came, the 
pharmacist refuses to sell the 
drug for him, when he didn’t feel 
comfortable with the observer 
then after time he sold the drug 
for the customer.  
 
19 Independent Male  
21-40 years 
Zega® 
/ 150 mg 
3 pack 
By 
customer 
without 
prescription 
Yes For pain  Familiar Sold the drug Because of requesting high 
quantities.  
20 Independent Male 
21-40 years 
Zega® 
/ 150 mg 
2 pack 
By 
customer 
without 
prescription 
Yes Fatigue and 
exhaustion 
Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
Because the drug not used for the 
treatment of fatigue and he 
requested large quantities.  
 
 
 
 
# Chain / 
Independent  
Pharmacy 
Participant 
gender/age 
Pregabalin 
product/ 
conc./ 
Quantity 
Request 
method 
Used 
before? 
Compliant by 
customer 
Customer 
Familiarity 
Pharmacist 
response  / reason, 
if not sold 
Suspicious reasons 
21 Independent Male 
21-40 years 
Zega® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
Yes For rest Familiar Sold the drug  The Customer didn’t clarify his 
disease and why he wants the 
medication. Unconvincing use of 
the drug and he just felt 
comfortable from the day.  
22 Independent Male  
Less than 
20 years 
Lyrica® 
/ 75 mg 
1 strip 
By 
customer 
without 
prescription 
Yes For rest   Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
The way of asking, appearance 
and no prescription. 
 
23 Independent Male  
21-40 years 
 
Regab® 
/ 75 mg 
1 pack 
By 
customer 
without 
prescription 
 
Yes To induce  relaxation 
in anger episode 
Familiar Sold the drug Because the customer used it for 
anger episode and he is young in 
age. 
24 Independent Male  
21-40 years 
 
Zega® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription 
No  To  improve mood  Familiar Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
The pharmacist told that this 
customer is known and he 
requested the drug to improve 
his mood after his dad death. 
25 Chain Female 
21-40 years 
Lyrica® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription 
Yes For mood Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
The way of asking, appearance 
and no prescription.  
 
26 Chain Male 
21-40 years 
Lyrica® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Refused to mention 
for his friend  
Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
The way of asking, appearance 
and no prescription.  
 
27 Chain Male  
21-40 years 
 
Lyrica® 
/ 75 mg 
1 strip 
By 
customer 
without 
prescription 
Yes For mood Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
The way of asking, appearance 
and no prescription.  
 
# Chain / 
Independent  
Pharmacy 
Participant 
gender/age 
Pregabalin 
product/ 
conc./ 
Quantity 
Request 
method 
Used 
before? 
Compliant by 
customer 
Customer 
Familiarity 
Pharmacist 
response  / reason, 
if not sold 
Suspicious reasons 
28 Independent Male  
21-40 years 
Galica® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes Knee pain  Non 
Familiar 
Refusing to sell 
under the pretext of 
lack of medicine 
 
 Because no scientific 
justification for using the drug in 
this customer. 
29 Independent Male  
21-40 years 
Lyrica® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes For stress  and anxiety Familiar Sold the drug Because there is no clear 
therapeutic reason for customer 
in using this drug. But the 
concern and pressure of life and 
this is not justified. 
30 Independent Female  
Less than 
20 years 
Galica® 
/ 75 mg 
1 strip 
 
By 
customer 
without 
prescription 
Yes Psychological anxiety Familiar Sold the drug  The pharmacist told that this 
customer is repeatedly requested 
the drug for pain. 
31 Independent Male  
21-40 years 
Galica® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
Yes Psychological_anxiety Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
When we asking the customer 
about the use of this drug, his 
answer not convincing. 
32 Independent Male 
21-40 years 
Neogaba® 
/ 150 mg 
1 pack 
By 
customer 
without 
prescription 
Yes Psychological state Non 
Familiar 
Refusing to sell 
under the pretext of 
the absence of a 
prescription 
 
Because the customer stated that 
he  used this drug for 
psychological reason. 
33 Independent Male  
21-40 years 
Galica® 
/ 300 mg 
1 pack 
By 
customer 
without 
prescription 
 
Yes For rest and deal with 
other people 
Non 
Familiar 
Sold the drug Because the customer stated that 
he has a psychological disorder 
and anxiety. That he feels better 
with this drug.  
34 Independent Male  
21-40 years 
Zega® 
/ 150 mg 
1 strip 
By 
customer 
without 
prescription 
 
Yes To induce mood and 
rest 
Familiar Sold the drug The pharmacist told that this 
customer himself stated that this 
drug causes him rest and good 
mood. 
  
 
 
 
35 Independent Male  
21-40 years 
Galica® 
/ 300 mg 
 
1 strip 
By 
customer 
without 
prescription 
Yes Spinal disc Non 
Familiar 
Sold the drug  Appearance, young in age and 
his way of asking. In addition, 
when I was there, the pharmacist 
felt scared and told the customer 
to bring a prescription with him 
tomorrow and take his number in 
front of me to keep it.  
